Image Image

Cooperation

Cooperation

We have established a good relationship with global and regional partners in project introduction and external cooperation.

In 2013, we licensed-in Troxacitabine from Yale University. In 2015, we licensed-in Clevudine, an anti-Hepatitis B drug, from Yale University the early development of which our founder was involved in. In 2019, we licensed-in the new anticancer drug Siroquine (JP001). HebaBiz Biotech is regarded internationally as an ideal partner to develop the Chinese market due to our strong product development capability and project experience.

Image
Image
Yale University

Yale University is a world-renowned private research university and the third oldest institution of higher learning in the United States. Yale University is one of the 14 founding institutions of the Association of American Universities and a member of the prestigious Ivy League.

Yale University School of Medicine ranks among the top ten medical schools in the world.

Image
JohnPro Biotech Inc.

JohnPro Biotech Inc. focuses on a “hidden drug pipeline” that most companies may not see as the backbone for cancer research. The founder of the company is a clinical oncology expert, with more than 30 years of clinical cancer treatment experience, leading a professional independent research and development team, inputting continuous efforts to study in the areas of anti-cancer drugs and cell medical technology. With expectorations to benefit patients, they continue to look for a new direction for the future of cancer treatment. JohnPro Biotech continues to develop innovative therapies that can be immediately applied for clinical purposes through acute clinical observation and in response to patient needs and feedback, and repeatedly verified via their biochemistry and immunology technology patent platform.